Women’s Health Therapeutics: Discovery to Development
Novel Drug Targets, Modalities, Technologies Driving Breakthrough Therapies
4/13/2027 - April 14, 2027 ALL TIMES PDT
Women’s health has long been overlooked in drug discovery, and the path to therapeutic progress remains complex, with insufficient R&D investment, limited disease understanding, a lack of relevant preclinical models, and inadequate clinical trial design and management. Women’s Health Therapeutics: Discovery to Development brings together drug developers, clinicians, and technology leaders working across target discovery, drug design, translational research, and the implementation of innovative tools and AI models, to discuss how the field can move ahead to launch much-needed, high-impact therapies. Join leaders from pharma, biotech, academia, technology companies, and investors to tackle the scientific and strategic barriers and make transformative treatments available for improving women’s health.

Tuesday, April 13

PLENARY KEYNOTE SESSION

Organizer's Welcome Remarks

Chairperson's Remarks

Michele M. Oshman, Chief Patient Advocate, Senior Vice President, Alliance Development, Biotechnology Innovation Organization (BIO) , Chief Patient Advocate & Sr VP Alliance , Patient Advocacy Ctr of Excellence , Biotechnology Innovation Organization

Panel Moderator:

PLENARY KEYNOTE PANEL:
It Takes a Village: A Cross-Sector Conversation on Innovation in Women's Health

Photo of Michele M. Oshman, Chief Patient Advocate, Senior Vice President, Alliance Development, Biotechnology Innovation Organization (BIO) , Chief Patient Advocate & Sr VP Alliance , Patient Advocacy Ctr of Excellence , Biotechnology Innovation Organization
Michele M. Oshman, Chief Patient Advocate, Senior Vice President, Alliance Development, Biotechnology Innovation Organization (BIO) , Chief Patient Advocate & Sr VP Alliance , Patient Advocacy Ctr of Excellence , Biotechnology Innovation Organization

Panelists:

Photo of Michael Annichine, CEO, Magee-Womens Research Institute & Foundation , CEO , Magee-Womens Research Institute & Foundation
Michael Annichine, CEO, Magee-Womens Research Institute & Foundation , CEO , Magee-Womens Research Institute & Foundation
Photo of Laura Cohen, JD, Vice President, Alzheimer's Environment Shaping, Lilly Neuroscience, Eli Lilly and Company , VP Alzheimer's Environment Shaping , Lilly Neuroscience , Eli Lilly & Co
Laura Cohen, JD, Vice President, Alzheimer's Environment Shaping, Lilly Neuroscience, Eli Lilly and Company , VP Alzheimer's Environment Shaping , Lilly Neuroscience , Eli Lilly & Co
Photo of Jayne Morgan, MD, Vice President, Hello Heart , Vice President , Hello Heart
Jayne Morgan, MD, Vice President, Hello Heart , Vice President , Hello Heart
Photo of Mallika Mundkur, MD, Former Deputy Chief Medical Officer, FDA , Former Deputy Chief Medical Officer, FDA; Executive Advisor , Nariyal Advisory
Mallika Mundkur, MD, Former Deputy Chief Medical Officer, FDA , Former Deputy Chief Medical Officer, FDA; Executive Advisor , Nariyal Advisory
Photo of Jenica Patterson, PhD, Senior Director, Women's Health Network, Milken Institute , Sr Dir , Women's Health Network , Milken Institute
Jenica Patterson, PhD, Senior Director, Women's Health Network, Milken Institute , Sr Dir , Women's Health Network , Milken Institute

Connect and Recharge Refreshment Break with Exhibit and Poster Viewing (Sponsorship Opportunity Available)

Organizer's Remarks

ADDRESSING SEX-BASED DIFFERENCES FOR CHRONIC CONDITIONS

Chairperson's Remarks

Sarah Temkin, MD, FACS Senior Director, Early Detection, American Cancer Society , Senior Director , Early Detection , American Cancer Society

Closing the Therapeutic Gap: Rethinking Chronic Conditions in Women

Photo of Sarah Temkin, MD, FACS Senior Director, Early Detection, American Cancer Society , Senior Director , Early Detection , American Cancer Society
Sarah Temkin, MD, FACS Senior Director, Early Detection, American Cancer Society , Senior Director , Early Detection , American Cancer Society

Women bear a disproportionate burden of many chronic diseases, yet the evidence base guiding their prevention and treatment remains incomplete. Despite growing investment in women’s health, female-specific biology is inconsistently incorporated into the development of novel therapeutics. This presentation will explore opportunities to better integrate female physiology, disease mechanisms, and life-course factors across the therapeutic development continuum. Differences in hormonal milieu, immune function, metabolism, and disease trajectories influence treatment response and adverse events, and should be considered. Deliberate attention to female biology can strengthen drug discovery and development and ultimately enable therapies that better reflect the health needs of women.

FEATURED PRESENTATION: Sex Differences in Cardiovascular Disease—Opportunities for Innovation

Photo of Kathryn Rexrode, MD, MPH, Chief Academic Officer & Chief, Division of Women’s Health, Brigham & Women’s Hospital , Chief Academic Officer & Chief, Division of Women’s Health , Medicine , Brigham & Women’s Hospital
Kathryn Rexrode, MD, MPH, Chief Academic Officer & Chief, Division of Women’s Health, Brigham & Women’s Hospital , Chief Academic Officer & Chief, Division of Women’s Health , Medicine , Brigham & Women’s Hospital

While cardiovascular disease is the leading cause of death in both men and women, there are important sex differences. Women have a higher lifetime risk of stroke, and higher risk of certain forms of heart failure and specific types of heart disease including microvascular disease, spontaneous coronary artery dissection, and takotsubo’s cardiomyopathy. These sex differences offer opportunities for innovations in diagnostics and therapeutics that can improve outcomes for women and all individuals.

Sex as a Biological Variable in Drug Safety: Evidence, Limits, and What Comes Next

Photo of Christian Andersen, PhD, Senior Scientist II, Nonclinical Development, Antares Therapeutics , Senior Scientist II , Nonclinical Development , Antares Therapeutics
Christian Andersen, PhD, Senior Scientist II, Nonclinical Development, Antares Therapeutics , Senior Scientist II , Nonclinical Development , Antares Therapeutics

A 1977 FDA guideline, written in the wake of thalidomide and DES, kept women of childbearing potential out of early trials. That rule then seeped upstream into animal and cell work. It took about thirty years for the correction to reach clinical trials and drug development—but it stopped short. In a set of regulatory dossiers, both sexes show up in every toxicology study, while female animals appear in just 9% of pharmacodynamics studies. The cost is measurable: of 86 drugs, 96% of those with female-biased pharmacokinetics had female-biased adverse reactions, versus 29% concordance in men. The talk traces that history, sorts out where the evidence for sex effects is strong and where the field overstates it, and asks which human in vitro systems could work as new approach methodologies for sex-specific risk—and as relevant models for new modalities.

Barriers and Solutions in Women's Health Research and Clinical Care: A Call to Action

Photo of Judith Regensteiner, PhD, Distinguished Professor, Internal Medicine; Director, Ludeman Family Center for Women’s Health Research, University of Colorado Denver , Distinguished Professor , Internal Medicine , Univ Of Colorado Denver
Judith Regensteiner, PhD, Distinguished Professor, Internal Medicine; Director, Ludeman Family Center for Women’s Health Research, University of Colorado Denver , Distinguished Professor , Internal Medicine , Univ Of Colorado Denver

There are significant differences between the sexes affecting prevalence, incidence, and severity over a broad range of diseases. Because women were excluded from most research until 1993, the prevention, diagnosis, and treatment of chronic diseases in women continues to be based primarily on findings in men, and sex-specific clinical guidelines are lacking. Research is needed to understand how relevant biological sex differences inform sex-specific prevention, diagnosis, and treatment strategies.

Q&A with Session Speakers

Women's Health Rocks Reception with Exhibit and Poster Viewing

Close of Day

Wednesday, April 14

Registration Open and Morning Coffee

INNOVATIVE THERAPEUTICS FOR WOMEN-RELATED DISORDERS

Chairperson's Remarks

Aritro Sen, PhD, Co-Founder & CSO, Maipl Therapeutics Inc. , Co-Founder & CSO , Maipl Therapeutics Inc.

FEATURED PRESENTATION: Breaking the Cycle—Targeting the FP Receptor in Dysmenorrhea and Endometriosis

Photo of Aritro Sen, PhD, Co-Founder & CSO, Maipl Therapeutics Inc. , Co-Founder & CSO , Maipl Therapeutics Inc.
Aritro Sen, PhD, Co-Founder & CSO, Maipl Therapeutics Inc. , Co-Founder & CSO , Maipl Therapeutics Inc.

This presentation will highlight the prostaglandin F2a (FP) receptor as a therapeutic target for primary dysmenorrhea and endometriosis-associated pain. Evidence supports a role for excessive FP signaling in uterine hypercontractility and pain that can persist despite NSAID treatment. We will discuss the rationale for developing selective, oral small-molecule FP antagonists as a non-hormonal approach to directly block FP-mediated signaling and address an important unmet clinical need.

Microbiome-Based Therapeutics for Endometriosis: From Causal Discovery to Clinical Translation

Photo of Rama Kommagani, PhD, Roger D. Rossen Endowed Professor of Reproductive Pathology, Baylor College of Medicine , R D Rossen Endowed Professor of Reproductive Pathology , Immunology & Molecular Virology & Microbiology , Baylor College of Medicine
Rama Kommagani, PhD, Roger D. Rossen Endowed Professor of Reproductive Pathology, Baylor College of Medicine , R D Rossen Endowed Professor of Reproductive Pathology , Immunology & Molecular Virology & Microbiology , Baylor College of Medicine

The gut microbiome has emerged as a promising therapeutic target in endometriosis. This talk will discuss mechanistic and causal evidence linking gut microbes to disease progression and explore opportunities to translate these findings into microbiome-based therapies, biomarkers, and precision medicine approaches that may improve outcomes for women with endometriosis.

Bridging Engineering and Biology: New Frontiers in Ovarian Function Restoration and Fertility Research

Photo of Ariella Shikanov, PhD, Professor, Biomedical Engineering, University of Michigan , Professor , Biomedical Engineering , University of Michigan
Ariella Shikanov, PhD, Professor, Biomedical Engineering, University of Michigan , Professor , Biomedical Engineering , University of Michigan

Chemotherapy and radiation cause premature ovarian insufficiency and infertility in young cancer survivors, and hormone replacement restores only some ovarian hormones, without natural cyclicity. My lab developed an immune-isolating hydrogel capsule that restored estrous cycles and estradiol production after implanting human ovarian tissue in mice, and biomimetic matrices that support in vitro follicle development. Our spatial atlas of the human ovary guides these platforms toward restoring fertility and ovarian function.

Ovarian Fibrosis: A Measurable and Targetable Hallmark of Human Reproductive Aging

Photo of Elnur Babayev, MD, MSc., Assistant Professor, Reproductive Endocrinology and Infertility, Department of Obstetrics & Gynecology, Northwestern University , Assistant Professor, Reproductive Endocrinology and Infertility , Obstetrics & Gynecology , Northwestern University
Elnur Babayev, MD, MSc., Assistant Professor, Reproductive Endocrinology and Infertility, Department of Obstetrics & Gynecology, Northwestern University , Assistant Professor, Reproductive Endocrinology and Infertility , Obstetrics & Gynecology , Northwestern University

Ovarian aging is a major driver of infertility and age-related health decline in women, yet its underlying mechanisms remain poorly defined. Using multimodal profiling that integrates shear wave elastography, extracellular matrix fingerprinting, and single-cell transcriptomics, we demonstrate that ovarian fibrosis is a quantifiable hallmark of human reproductive aging. Ovarian stiffness is associated with diminished reproductive function, and our work identifies fibrosis as a promising biomarker and therapeutic target for extending reproductive longevity.

Q&A with Session Speakers

Interactive Breakout Discussions Block

INTERACTIVE BREAKOUT DISCUSSIONS

Interactive Breakout Discussions

Interactive Breakout Discussions are informal, moderated discussions, allowing participants to exchange ideas and experiences and develop future collaborations around a focused topic. Each discussion will be led by a facilitator(s) who keeps the discussion on track and the group engaged. To get the most out of this format, please come prepared to share examples from your work, be a part of a collective, problem-solving session, and participate in active idea sharing. Please visit the Interactive Breakout Discussions page on the conference website for a complete listing of topics and descriptions.

Presentation to be Announced

Continue Conversations over Coffee with Exhibit and Poster Viewing (Sponsorship Opportunity Available)

PURSUING NEW DRUG TARGETS & MODALITIES

Chairperson's Remarks

Wendy Young, PhD, Scientific Advisor & Board Director; Former Senior Vice President, Small Molecule Drug Discovery, Genentech , Scientific Advisor & Board Director & Former SVP Genentech

FEATURED PRESENTATION: No More "Morning Sickness": Taking HG Breakthroughs from the Lab to the Clinic

Photo of Marlena Fejzo, PhD, Assistant Professor, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California , Assistant Professor , Center for Genetic Epidemiology, Population and Public Health Sciences, Keck School of Medicine , USC
Marlena Fejzo, PhD, Assistant Professor, Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California , Assistant Professor , Center for Genetic Epidemiology, Population and Public Health Sciences, Keck School of Medicine , USC

Most pregnancies are affected by morning sickness, but 14% of pregnancies have severe symptoms that are prolonged, debilitating and can be life-threatening for mother and baby. We found the main cause is maternal hypersensitivity to the nausea and vomiting hormone GDF15 produced by the placenta. The discovery of this mechanism has introduced new ways to predict, prevent, and treat it, and clinical trials are in progress to potentially diminish suffering.

Developing Targeted Non-Hormonal Therapeutics to Treat Uterine Fibroids

Photo of Amanda Pinheiro, PhD, Co-Founder, Evina Biosciences , Co-founder , Evina Biosciences
Amanda Pinheiro, PhD, Co-Founder, Evina Biosciences , Co-founder , Evina Biosciences

Uterine fibroids affect more than 14 million symptomatic women in the U.S., yet treatment remains dominated by invasive procedures and hormonal therapies with significant limitations. This presentation will describe our efforts to translate the discovery of TDO2 as a therapeutic target downstream of MED12 mutations into a non-hormonal, precision treatment for uterine fibroids, highlighting the scientific rationale, early drug-development strategy, and path toward preclinical validation.

4HER2: Radioligands in Women’s Health

Photo of Elcin Zan, MD, Chair, Division of Nuclear Medicine, Cleveland Clinic , Chair, Nuclear Medicine , Imaging Institute , Cleveland Clinic
Elcin Zan, MD, Chair, Division of Nuclear Medicine, Cleveland Clinic , Chair, Nuclear Medicine , Imaging Institute , Cleveland Clinic

Radioligand therapy is seeing growing focus on women’s health, supported by dedicated research, development effort, and investment. 4HER2 (For HER2 Radioligands and Beyond) highlights the opportunity in HER2-positive breast cancer as well as other relevant indications, including ovarian cancer and selected autoimmune disorders. This talk reviews promising clinical and preclinical programs, the progress already underway, and how these targeted agents can improve outcomes for women and also, men.

Targeting Wee2 for Non-Hormonal Contraception: Discovery and Characterization of First-in-Class Selective Small Molecule Inhibitors

Photo of Felicia Gray, PhD, Director, Biology, Schrödinger Inc. , Director , Biology , Schrödinger Inc.
Felicia Gray, PhD, Director, Biology, Schrödinger Inc. , Director , Biology , Schrödinger Inc.

Wee2 inhibition presents a novel opportunity for non-hormonal contraception, validated by human genetics in female infertility. Here, we present the discovery and characterization of first-in-class, potent, and highly selective Wee2 small-molecule inhibitors. These compounds effectively block egg activation in mouse and human in vitro models while exhibiting favorable safety profiles in preliminary in vitro ovarian function and teratogenicity assessments.

Q&A with Session Speakers

Session Break

IMPACT OF AI/ML & NEW MODELS IN ACCELERATING DRUG DEVELOPMENT

Chairperson's Remarks

Shruthi Bharadwaj, PhD, Executive Director, AI Drug Discovery Analytics, Revolution Medicines , Executive Director , AI Drug Discovery Analytics , Revolution Medicines

FEATURED PRESENTATION: AI and Its Impact on Closing the Gender Gap

Photo of Petrina Kamya, PhD, Global Head of AI Platforms and Vice President, Insilico Medicine; President, Insilico Medicine Canada , Global Head of AI Platforms, VP , Insilico Medicine, Canada
Petrina Kamya, PhD, Global Head of AI Platforms and Vice President, Insilico Medicine; President, Insilico Medicine Canada , Global Head of AI Platforms, VP , Insilico Medicine, Canada

From Scientific Blind Spots to Breakthrough Innovation in Women's Health

Photo of Angelika Fretzen, PhD, MBA, COO & Technology Translation Director, Wyss Institute, Harvard University , COO & Technology Translation Director , Wyss Institute for Biologically Inspired Engineering
Angelika Fretzen, PhD, MBA, COO & Technology Translation Director, Wyss Institute, Harvard University , COO & Technology Translation Director , Wyss Institute for Biologically Inspired Engineering

Women’s health represents an enormous, untapped opportunity for biomedical innovation and investment. Advances in bioengineering, patient-derived disease models, biomarker discovery, and AI are unlocking new insights into female biology across diverse diseases. Yet critical gaps remain between scientific discovery, clinical translation, and commercialization. The Wyss Institute’s Women’s Health Catalyst continues to explore new partnership models to bridge gaps, accelerate innovation, and build the next generation of transformative women’s health companies.

Beyond Representation: Can Model Informed Drug Development (MIDD) Close the Female Evidence Gap?

Photo of Raquel Mura, PharmD, Founder, RGM Life Sciences Consulting; Former Vice President & Head, R&D North America, Sanofi , Founder , RGM Life Sciences Consulting
Raquel Mura, PharmD, Founder, RGM Life Sciences Consulting; Former Vice President & Head, R&D North America, Sanofi , Founder , RGM Life Sciences Consulting

Increasing women’s representation in clinical research is critical. This session explores how model-informed drug development (MIDD) can translate biological differences related to sex and female life stages into better decisions about dosing, trial design, evidence generation, benefit-risk, and treatment. It covers population PK/PD, PBPK, exposure-response and disease modeling, and virtual populations across reproductive age, pregnancy, lactation, perimenopause, menopause, and aging, and examines where empirical clinical evidence remains essential.

Perimenopause, Menopause, and the Underserved Majority

Photo of Michael Liebman, PhD, Managing Director, IPQ Analytics, LLC , Managing Dir & Co Founder , IPQ Analytics LLC
Michael Liebman, PhD, Managing Director, IPQ Analytics, LLC , Managing Dir & Co Founder , IPQ Analytics LLC

Approximately 40% of every woman’s life can be described as either peri- or post-menopausal yet our understanding of this individualized transition remains limited to a collection of symptoms. We are developing a model of a woman’s life journey, beginning well before the first hot flash, to help women understand and manage their own transition and personalize their risk for breast cancer, cardiovascular disease, and osteoporosis.

AI to Discover Drugs for Women's Health

Photo of Shridhar Narayanan, PhD, Co-Founder & CSO, Drug Discovery & Development, Peptris Technologies Pvt Ltd , Co-Founder & CSO , Drug Discovery & Dev , Peptris Technologies Pvt Ltd
Shridhar Narayanan, PhD, Co-Founder & CSO, Drug Discovery & Development, Peptris Technologies Pvt Ltd , Co-Founder & CSO , Drug Discovery & Dev , Peptris Technologies Pvt Ltd

Peptris has developed its proprietary algorithms which are being used to identify new drugs or repurpose/rescue existing molecules for various women's health indications.

Close of Conference


For more details on the conference, please contact:

Tanuja Koppal, PhD

Senior Conference Director

Cambridge Healthtech Institute

Email: [email protected]

 

For sponsorship information, please contact:

Kristin Skahan

Senior Business Development Manager

Cambridge Healthtech Institute

Phone: 781-429-9985

Email: [email protected]


Request Brochure

Programs